Search PubMed⌕ Search

Biomedical subjects

F Zintl

Publications and source records attributed to F Zintl.

182 records · Page 11Linked to original sources

Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL).

The expression of the resistance-related proteins P-glycoprotein 170 (P-170), glutathione-S-transferase pi (GST-pi), topoisomerase II (Topo II), thymidylate synthase (TS) and metallothionein (MT) was investigated in leukemic cells of 19 children with newly diagnosed acute nonlymphoblastic leukemia. P-170 was expressed in 84%, GST-pi in 37%, TS in 47%, MT in 68%, and Topo II was downregulated in 37% of the cases investigated. No resistance factors were found in two patients, one positive factor was found in two patients, three factors in three patients, four factors in 7 patients, and all resistance factors investigated were present in one patient. Patients who developed a relapse expressed more than two resistance mechanisms significantly more often than patients who remained in remission (p = 0.005). The probability of continuous first remission was significantly lower where more than two resistance mechanisms were expressed. The results indicate that the higher the number of resistance-related proteins in childhood ANLL the poorer the prognosis of the patients.

ATP Binding Cassette Transporter, Subfamily B, Mem↗

nm23-H1 protein expression in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.

In a retrospective study, immunocytochemistry was used to analyze the cells of 62 newly diagnosed and 28 relapsed childhood acute lymphoblastic leukemias (ALL) for the expression of nm23-H1 protein. Of the 62 newly diagnosed ALL, only 9 cases exhibited positive staining (15%) while 10 of the 28 relapsed ALL did (36%). This difference is statistically significant (P = 0.03, Fisher's exact test). Furthermore, the presence of mutations in the exons 1-5 was investigated by RT-PCR and single-strand conformation polymorphism (SSCP) analysis. No mutations could be detected in either the newly diagnosed or relapsed ALL. This finding suggests that nm23-H1 mutations may be a rare event in ALL.

Biomarkers, Tumor↗